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Summary Immunohistochemical antibody techniques for detection of oestrogen receptors (ER) were applied
to formalin fixed, paraffin embedded sections from 62 primary breast cancers, the metastases of their original
regional lymph nodes (29 cases), bone marrow carcinosis (43 cases) and liver metastases (20 cases). Forty per
cent of the primary tumours and 31% of the regional lymph node metastases were ER positive; in contrast,
less than 20% of liver and bone marrow metastases were ER positive. The ER status of regional lymph node
metastases was concordant with that of the primary tumour in 90% of the cases. The concordance rate was
75% for liver metastases and 58% for bone metastases. Patients with ER positive primary tumours had
recurrence significantly more often in bone; ER negative tumours recurred more often in the liver. The
survival after recurrence (SAR) was significantly related to the ER status of the primary tumour and to that
of the regional lymph node metastases. In contrast, the SAR was not associated with the ER status of bone
marrow carcinosis or liver metastases. Cox analyses showed that age and ER status of the primary tumour
were the most important independent prognostic factors compared to other clinical, therapeutic,
pathoanatomical and biochemical features. The study supports the hypothesis that tumour cell clones with
different ER content are selected and adapted to grow in various anatomical sites. Moreover, the ER status
of the primary tumour seems to be more important for the prognosis than the ER status of bone and liver
metastases.
The presence of oestrogen receptors (ERs) is associated with
a prolonged survival in patients with both primary and
recurrent breast cancer. This probability applies both to an
increased effect of endocrine therapy in receptor positive
patients (Alanko et al., 1985; Howell et al., 1984; Rose et al.,
1985) and to qualitative differences between ER positive and
negative tumours (Clark et al., 1987; Parl et al., 1984; Shek
et al., 1987).
The ER status of a given tumour should be regarded as a
reflection of the average receptor content from cell clones
with varying receptor contents. It is unknown whether clones
with different receptor content metastasise to different
organs or whether it is the 'average' ER content per se which
reflects specific biological subtypes. The purpose of the
present study is to describe and to compare the
immunohistochemical ER content in primary breast cancer,
involved regional lymph nodes and subsequent distant
metastases. Moreover, prognostic importance of site-specific
differences has been investigated.
Materials and methods
The patients all participated in a prospective investigation
programme for patients with recurrent breast cancer. The
organisation and results of this study have been published
previously (Kamby et al., 1987b). In brief, patients were
considered as having first recurrence when any recurrence
was detected after primary treatment of localised breast
cancer. Patients with primary locally advanced breast cancer
or with distant metastases at the time of initial diagnosis
were also included. Patients older than 75 years of age and
patients with previous or concomitant other primary cancers
were not included.
The investigation programme included history, physical
examination, blood tests, ultrasonic scanning of the liver,
chest X-rays, radiographic bone survey, bone scintigraphy
and bilateral posterior iliac crest biopsy. All patients who
had suggestive signs of recurrence on ultrasound scanning
had a biopsy performed with a sure-cut needle in order to
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obtain tissue for histological verification of metastasis
(Kamby et al., 1987a).
All metastatic sites detected within 1 month after the
diagnosis of the first site of metastasis were grouped together
and designated as the sites of first recurrence. The sites of
metastases were recorded according to anatomical location.
When the number of sites was calculated, the presence of
recurrence in each anatomical location counted for one,
irrespective of the number of tumour deposits within each
site.
Among the 394 evaluable patients who entered the
investigation programme, 111 patients had histologically
verified liver metastases and/or bone marrow carcinosis. Of
these, paraffin embedded specimens from the primary
tumour were available from 76 patients. In 14 cases, either
the primary tumour specimen (eight patients) or the
metastatic tissue (six patients) was not evaluable by the
immunohistochemical method. This leaves 62 patients with
immunohistochemical ER determination of both the primary
tumour and a metastasis. Twenty-nine of the patients had
locoregional metastases at the time of primary diagnosis.
The ER status of these metastases was also determined.
The ER analyses were made on sections from formalin
fixed and paraffin embedded tissue blocks from the primary
tumour, the concomitant regional lymph node metastases,
the sure-cut liver biopsies and the positive bone marrow
aspiration clots. The metastatic samples were obtained a
median of 27 months (25-75%: 11-50 months) after initial
presentation.
The method for the immunohistochemical detection of ER
has beeen described in detail elsewhere (Rasmussen &
Kamby, 1989). Briefly, after dehydration in xylol and
decreasing concentrations of alcohol, the sections were
incubated with trypsin, 0.1%, for 2h. After being rinsed in
PBS, the sections were incubated with 5% human serum in
order to reduce background staining. The incubation with
primary antibody, 10#gml-' in 5% human serum, took
place overnight at 40°C. The antibody was a special supply
from G. Greene, Ben Mai Institute, University of Chicago. It
is known to react reasonably well on paraffin embedded
material (De Rosa et al., 1987). After repeated rinsing, the
sections were incubated with peroxidase-conjugated goat-
antirat, 1:50 in 5% human serum, for 30min. A positive
reaction was visualised with diamino-benzidine (DAB). A
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Table I Patient characteristics, distribution of patients according to oestrogen receptor
content of the primary tumour and clinical and pathoanatomical characteristics
Oestrogen receptor content
None Low High
n=37a n=6 n=19 P
Age
Recurrence-free interval
Systemic adjuvant therapy
Systemic therapy after recurrence
Laterality
Location
Tumour size
Lymph node status
No. of positive nodes
<45 years
45-55 years
>55 years
<24 months
>24 months
none
endocrineb
other
none
endocrineb
other
right
left
lateral
medial
central
<3cm
>3cm
negative
positive
<2
>2
9
16
12
1
3
2
14 3 8
23 3 11
9
8
20
0
29
8
24
13
23
7
3
16
20
2
1
3
1
4
1
4
2
4
1
1
1
5
10 0 4
20 5 9
12 0 4
8 5 5
aN is the total (maximum) number of patients in each group; b+ chemotherapy.
light counter-stain was given with a few dips in haema-
toxylin. A known ER positive breast carcinoma was used as
positive control. As negative control the primary antibody
was omitted.
The reaction was semi-quantitatively estimated as negative
(no staining), weakly positive (a few lightly stained cells) and
positive (several, medium to heavily stained cells). When
grouping according to ER status, the weakly positive
tumours were grouped with the ER positive tumours.
Background staining was negligible. Thus, staining was never
found in normal haemapoietic cells. Liver cells often showed
a slightly uniform light brown colouring of the cytoplasm,
but the nuclei were invariably negative.
Treatment
The primary treatment was simple mastectomy with partial
axillary sampling. Stage II patients (tumours>5cm, local
invasion or positive nodes) received radiotherapy and were
thereafter either observed or given adjuvant chemotherapy
(premenopausal patients) or tamoxifen (post-menopausal
patients) (Andersen et al., 1981).
Treatment of recurrent disease
Premenopausal patients were castrated with irradiation and
received combination chemotherapy. Post-menopausal
patients below the age of 65 years received tamoxifen and
three-drug combination chemotherapy. Patients above 65
years of age received endocrine therapy only.
Statistical methods
For comparison of qualitative data, the X2 test and the
Mann-Whitney rank sum test for unpaired samples were
used (Bross, 1954). Survival data were calculated from the
time of first recurrence (i.e. survival after recurrence, SAR).
Univariate survival distributions were estimated using the
Kaplan-Meier product limit procedure, and the log.rank test
was used to evaluate the differences in survival rates (Peto et
al., 1977). The Cox proportional hazards model (Cox, 1972)
was used to test the influence of univariate significant
features on the effect of ER status on SAR. A P value of
less than 0.05 was considered significant.
Results
Patient characteristics
The mean age at the time of recurrence was 53 years (range
30-74 years). Of the primary tumours, 58% were >3cm,
and two-thirds of the patients had positive axillary nodes.
Seventy per cent received systemic adjuvant therapy;
adjuvant endocrine therapy with or without chemotherapy
was given to 24% of the patients. Within two years 40% of
the patients had recurrence. The mediation duration of the
recurrence-free interval was 27 months (25-75% fractiles
11-50 months). Table I shows that both pathoanatomical
and demographic as well as clinical characteristics were
unassociated with the ER content of the primary tumour.
Oestrogen receptor data
Immunohistochemical examination of tumour tissue from
both the primary tumour and a metastasis was possible in 62
patients (43 of these had bone marrow carcinosis; 20 patients
had liver metastases; one patient had both bone and liver
lesions). The ER content of metastases from regional lymph
nodes was determined in 29 of the patients.
Sixty per cent of the primary tumours did not contain ER
(i.e. they were ER negative). The prevalence of ER negativity
increased with increasing metastatic spread. Thus, 82% and
95% of the bone and liver metastases were ER negative
compared to 69% of the regional lymph node metastases. In
Table II Marginal distributions of patients according to site of
detection and oestrogen receptor (ER) content (semiquantitatively)
Oestrogen receptor content
None Low High Total
Site of detection n (%) n (%) n (%) n (%)
Primary tumour 37 (60) 6 (10) 19 (30) 62 (100)
Regional lymph
nodes 20 (69) 4 (14) 5 (17) 29 (100)
Bone marrow 35 (82) 4 (9) 4 (9) 43 (100)
Liver 19 (95) 0 (0) 1 (5) 20 (100)
n indicates the number of paients in each grooup, and percentages
are fractions of the total number of patients with measurable ER in
each site.
3
4
12
8
6
5
0
17
2
8
11
13
1
4
8
9
0.16
0.69
0.16
0.42
0.14
0.97
0.91
0.60
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contrast, less than 10% of the liver and bone marrow
metastases were ER rich, while 30% of the primary tumours
had a high ER content (Table II).
The ER status of metastases in regional lymph nodes was
concordant (+/ + or -/-) with the ER status of the primary
tumours in 90% of the patients. The concordance rates for
primary tumour versus bone marrow and versus liver
metastases were 58% and 75%, respectively (Table III).
Table III also shows that the discordance rate (ER positive
primary tumour/ER negative metastasis) was higher for
metastases in bone and liver compared to metastases in
regional lymph nodes.
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Figure 1 Distribution of patients according to number of
metastatic sites and oestrogen receptor (ER) status. The heights
of the columns represent the percentage of the total number of
patients in each group: ER negative (single hatched), 37 patients.
ER positive (double hatched), 25 patients.
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Figure 2 Anatomical distribution of metastases in patients with
oestrogen receptor (ER) positive (double hatched, 25 patients)
and ER negative (single hatched, 37 patients) primary tumours.
The heights of the columns reflect the percentage of the total
number of patients with recurrence in each group. *P<0.05.
Metastatic pattern
Most of the patients had recurrence in two or more sites
(67%). The number of metastatic sites was similar in patients
with ER positive and negative primary tumours (Figure 1,
P=0.34). The most common sites of recurrence were bone
and liver. (This was so, because patients with these
recurrences were selected for the present study.) ER positive
primary tumours recurred significantly more often in bone,
while ER negative tumours recurred more often in liver.
Other sites of recurrence occurred equally in ER positive and
negative patients (Figure 2).
Forty-six patients had radiological bone metastases, and
23 patients had more than two bone regions involved. The
extent (number) of radiographic bone lesions was similar in
ER positive and negative patients (P=0.14). The pre-
dominant radiographic morphology was osteolysis (77%)
followed by mixed (26%) and osteosclerotic (12%) lesions.
The radiological appearance of bone metastases was un-
associated with the ER content.
Survival data
The median period of observation after first recurrence was
39 months (range 26-55 months); at the time of follow-up
(May 1988), 51 patients (82%) had died. The median
survival after recurrence (SAR) was 10 months (25-75%
fractiles 3-26 months).
Univariate survival analyses of clinical and patho-
anatomical characteristics showed that increasing age,
decreased serum albumin and increasing number of
metastases were features of a short SAR. The SAR was not
significantly associated with differences in laterality and
location of the primary tumour, tumour size, regional lymph
node status, number of positive nodes, recurrence-free
interval, adjuvant therapy, number of bone metastases and
treatment of recurrent disease (Table IV).
The SAR was significantly related to the ER status of
both the primary tumour (P=0.01) and the regional lymph
node metastases (P=0.004) (Figure 3). In contrast, the SAR
was not associated with the ER status of bone marrow
carcinosis and liver metastases (Table V). In order to identify
patients with extremely poor prognosis, patients with
concordant ER negative tissues from both the primary
tumour and a metastasis were grouped together. The SAR of
these patients was compared with the survival of paients
with discordant or concordant ER positive tumours. Patients
with concordant ER negative primary tumours/regional
nodes, primary tumours/bone marrow or regional nodes/
bone marrow all had a significantly shorter survival than the
SAR of patients with other receptor profiles (Figure 4).
However, patients with liver metastases all had a very short
survival, irrespective of both the ER profile (Table V and
Figure 4).
Multivariate regression analyses
Table VI summarises the results of a model which initially
included ER status of the primary tumour, tumour size,
node status, adjuvant endocrine therapy and clinical
characteristics at the time of recurrence. The grouping of
these variables was as shown in Table IV. The analysis was
performed on 50 patients from whom a complete data set
was available. Forty of these patients have died. Stepwise
Table III Distribution of patients in relation to oestrogen receptor status and site of detection
Concordance Discordance Oestrogen receptor statusa Concordance Discordance
Primary rate rate
tumour metastasis (-/-) (-/+) (+/- ) (+/+) (-/- or +/+) (+ --)
Regional lymph nodes 17 0 3 9 90% 25%
Bone marrow 19 2 16 6 58% 73%
Liver 14 0 5 1 75% 83%
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Table IV Distribution of clinical and pathoanatomical features and their influence on survival after
recurrence
Survival
after recurrence
Variable
Age
Recurrence-free interval
Systemic adjuvant therapy
Systemic therapy after recurrence
Laterality
Location
Tumour size
Lymph node status
No. of positive nodes
No. of metastatic sites
No. of bone metastases
Serum albumin level
aMonths;
b+chemotherapy.
No. of
Category patients
<45 years
45-55 years
>55 years
<50 years
>50 years
<24 months
>24 months
none
endocrineb
other
none
endocrineb
other
right
left
lateral
medial
central
<3cm
>3cm
negative
positive
>2
2 1
2
>2
1-2
>2
normal
decreased
ER pos. (n = 25)
13
23
26
30
32
25
37
19
15
28
1
50
11
40
26
40
9
8
25
34
14
34
16
18
20
28
14
(25-75%
Mediana fractiles)
21
13
6
15
6
9
11
19
13
6
11
6
7
13
15
9
7
(5-27)
(3-28)
(3-19)
(6-28)
(2-19)
(5-24)
(3-25)
(7-28)
(4-24)
(2-24)
(4-25)
(2-44)
(3-24)
(4-27)
(3-26)
(7-13)
(3-28)
13 (5-25)
9 (2-24)
10
9
6
13
19
13
4
(3-20)
(4-24)
(2-19)
(4-27)
(6-25)
(3-27)
(2- 9)
23 19 (5-25)
23 14 (6-36)
35 23 (9-28)
15 9 (2-24)
P
0.4062
0.0352
0.9768
0.5477
0.3636
0.1463
0.7511
0.6266
0.1417
0.1908
0.0714
0.1509
0.0603
forward and backward selection procedures eliminated all
covariates except age and ER status. The hazard rate of
SAR for the group of patients with ER negative primary
tumours was approximately twice the rate for ER negative
patients (Table VI). The inclusion of knowledge of ER status
of regional nodes or bone marrow carcinosis did not
improve the regression equation significantly. This indicates
that if the ER status of the primary tumour is considered,
then knowledge of the ER status of regional nodes or bone
will yield no additional prognostic information.
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Figure 3 Survival after first recurrence by oestrogen receptor
(ER) status of primary tumour (a) and regional lymph node
metastases (b).
Discussion
The development of techniques for immunohistochemical
studies of paraffin sections has made it possible to apply this
method to greater retrospective series of biopsies (Andersen
et al., 1986). Thus, the present study was performed retro-
spectively on biopsies from a prospective, consecutive group
of patients who entered a protocolled investigation
programme for recurrent breast cancer.
The study shows that use of the immunohistochemical
method on paraffin embedded sections is possible. Moreover,
the immunohistochemical method has the advantage over the
biochemical method that it is possible to assess the tumour
heterogeneity. The results of the method have an acceptable
agreement with the biochemical method. Thus, we found an
overall concordance rate of 93% with the biochemical
method (Rasmussen & Kamby, 1989).
The relatively high proportion of ER negative primary
tumours (60%) may be due to the fact that all our patients
had distant recurrences. Thus, ER positive patients (with a
good prognosis) are more often without recurrence. Our
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Figure 4 Survival after first recurrence for patients with
concordant oestrogen receptor (ER) negative primary tumours/
metastases versus patients with other receptor profiles (-/+,
+/-, and +/+). (a) Primary tumour and regional nodes
(P=0.0008); (b) Primary tumour and bone marrow (P=0.0005);
(c) Primary tumour and liver (P=0.3819).
patients were not only selected among patients with
recurrence, but also among a subgroup of patients with a
particularly poor prognosis (i.e. distant metastases).
Moreover, a proportion of the ERs may be destroyed during
Table V Median duration of survival
specimen and oestrogen receptor (ER) st
the formalin fixation and paraffin embedding. Therefore, we
cannot exclude that some of our analyses are false negative.
However, the results obtained here have prognostic
significance, and for comparative purposes the actual
proportion of false negative tests is of minor importance,
since these tend to be equal in different groups.
There is a risk that slightly positive tumours are
misclassified as (false) ER negative when detected in
formalin fixed and paraffin embedded tissue. The loss of
receptors might conceal a relationship between ER status of
the metastases and the SAR. We therefore studied tumours
which were negative in more than one location, because
these may be regarded as more 'juvenile' negative than
tumours with discordant ER status. We compared the SAR
of patients who were concordant ER negative in the primary
tumour as well as in the metastases to the SAR of other
patients. These comparisons show a clearer prognostic
distinction between ER positive and negative patients.
However, the SAR of both ER positive and negative patients
was only a few months for patients with liver metastases.
This indicates that the presence of liver metastases always
should be regarded as a sign of poor prognosis, independent
of the ER status.
The investigation shows that the ER status of the primary
tumour and, to some extent, of the regional lymph node
metastases can be regarded as main prognostic factors. This
is in agreement with the findings of both Leclerq et al.
(1975) and Hoehn et al. (1979). The ER status of distant
metastases had no obvious relation to SAR. Liver metastases
were more frequently ER negative than bone metastases.
This may implicate that the ER status and the endocrine
responsiveness in a single location may make only a limited
contribution to the prognosis. Moreover, it explains why the
response rate to endocrine therapy is far from 100%, and it
may explain why the ER status of distant metastases is
unassociated with SR.
Theoretically, the ER status may influence survivavl by (1)
variations in the growth rate, (2) variations in the degree of
spread, or (3) differences in the anatomical location of the
metastases. ER negative tumours have a high labelling index
(Silvestrini, 1981) and a faster rate of progression (Kamby et
al., 1988). This indicates that the poor prognosis for ER
negative patients is due to a relatively high rate of growth
(Adami et al., 1985). The present study shows that the poor
prognosis for ER negative patients is probably not mediated
through a propensity to develop multiple metastases. Thus,
the number of metastatic sites was similar in ER positive
and negative patients. ER positive tumours had a propensity
to metastasise to bone, while ER negative tumours often
recurred in viscera. This pattern is in accordance with the
main part of the literature (Clark et al., 1987; Kamby et al.,
1988). This distribution is in agreement with the hypothesis
that the ER status also influences prognosis because of ER-
related variations in the pattern of spread.
In conclusion, the study shows that immunohistochemical
ER status of the primary tumour evaluated on paraffin
sections has independent prognostic importance for the
after first recurrence according to tissue
Survival
after recurrence
No. of Median (25-75%
Tissue ER status patients (months) fractiles) P
Primary tumour negative 37 7 (2-15)
positive 25 25 (7-36) 0.0011
Regional lymph nodes negative 20 4 (1-9)
positive 9 21 (7-27) 0.0039
Bone marrow negative 35 13 (5-38)
positive 8 19 (3-25) 0.9230
Liver negative 19 5 (2-14)
positive 1 3
C
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Table VI Results from Cox analyses considering the impact of oestrogen receptor
status and clinical and pathoanatomical features on the survival after first recurrence
Regression Standard Wald's
coefficient error statistics
Covariates f s.e. (fl) fl/s.e. (,l) P
Initial model
Age 0.05 0.03 2.09 0.03
Endocrine therapy
adjuvant 0.47 0.52 0.91 0.37
of recurrence -1.09 0.99 -1.10 0.23
Tumour size 0.16 0.17 0.97 0.33
Presence of positive nodes -0.15 0.10 -1.51 0.12
No. of metastatic sites 0.23 0.27 0.85 0.40
S-albumin 0.00 0.04 0.65 0.51
Oestrogen receptor statusa -0.80 0.37 -2.18 0.02
Final model
Age 0.04 0.02 1.88 0.05
Oestrogen receptor statusa -0.64 0.31 -2.06 0.02
aOf the primary tumour.
Analyses are based on a complete data set from 29 patients, of whom 24 (93%)
have died.
duration of post-recurrent survival in breast cancer. The
receptor contents of the primary tumour and of the
metastases were usually concordant, although there was a
tendency for lower receptor content in the metastases. The
high rate of concordance is related to the relatively high
prevalence of ER negative primary tumours (60%). Thus, a
shift from a negative primary tumour to positive metastases
was seen in only two patients with bone marrow carcinosis,
and in no patients with liver metastases. The reverse dis-
concordance rate (positive to negative) was 73% and 83%
for patients with bone and liver metastases, respectively. This
suggests that the decision on endocrine therapy should be
based on the ER status of the metastases.
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